PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Azoles - Market size and forecast 2018-2023 • Echinocandins - Market size and forecast 2018-2023 • Other drugs - Market size and forecast 2018-2023 • Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 10: MARKET TRENDS PART 11: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 12: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Astellas Pharma • Bayer • Fresenius • Merck • Pfizer PART 13: APPENDIX • Research methodology • List of abbreviations Exhibit 01: Years in consideration Exhibit 02: Global infectious disease treatment market Exhibit 03: Segments of global infectious disease treatment market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Azoles - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Azoles - Year-over-year growth 2019-2023 (%) Exhibit 22: Echinocandins - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Echinocandins - Year-over-year growth 2019-2023 (%) Exhibit 24: Other drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Other drugs - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by type Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Decision framework Exhibit 45: Impact of drivers and challenges Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: Astellas Pharma - Vendor overview Exhibit 52: Astellas Pharma - Business segments Exhibit 53: Astellas Pharma - Organizational developments Exhibit 54: Astellas Pharma - Geographic focus Exhibit 55: Astellas Pharma - Key offerings Exhibit 56: Astellas Pharma - Key customers Exhibit 57: Bayer - Vendor overview Exhibit 58: Bayer - Business segments Exhibit 59: Bayer - Organizational developments Exhibit 60: Bayer - Geographic focus Exhibit 61: Bayer - Segment focus Exhibit 62: Bayer - Key offerings Exhibit 63: Bayer - Key customers Exhibit 64: Fresenius - Vendor overview Exhibit 65: Fresenius - Business segments Exhibit 66: Fresenius - Organizational developments Exhibit 67: Fresenius - Geographic focus Exhibit 68: Fresenius - Segment focus Exhibit 69: Fresenius - Key offerings Exhibit 70: Fresenius - Key customers Exhibit 71: Merck - Vendor overview Exhibit 72: Merck - Business segments Exhibit 73: Merck - Organizational developments Exhibit 74: Merck - Geographic focus Exhibit 75: Merck - Segment focus Exhibit 76: Merck - Key offerings Exhibit 77: Merck - Key customers Exhibit 78: Pfizer - Vendor overview Exhibit 79: Pfizer - Business segments Exhibit 80: Pfizer - Organizational developments Exhibit 81: Pfizer - Geographic focus Exhibit 82: Pfizer - Segment focus Exhibit 83: Pfizer - Key offerings Exhibit 84: Pfizer - Key customers Exhibit 85: Validation techniques employed for market sizing Exhibit 86: List of abbreviations  

Astellas Pharma Bayer Fresenius Merck Pfizer